Life science technology company 10x Genomics Inc (Nasdaq:TXG) on Saturday introduced Atera, an in situ spatial biology platform designed to deliver whole-transcriptome spatial analysis with single-cell sensitivity at unprecedented scale.

According to 10x Genomics, Atera enables the complete measurement of biology, in its native context at single-cell resolution and at scale.

Atera is engineered to enable large-scale whole-transcriptome spatial studies across both fresh-frozen and FFPE tissue, supporting diverse applications in both discovery and translational research.

"Biology is inherently complex, and as much progress as we have made, we still understand only a fraction of how it works," said Serge Saxonov, CEO and co-founder of 10x Genomics. "Progress in medicine depends on confronting that complexity directly, which requires measuring biology as it actually functions: systems of individual cells, expressing specific transcripts, in precise locations within tissue. Atera removes the trade-offs that have constrained research, unlocking a new era of insight that will transform our understanding of science and human health."

Data presented at the American Association for Cancer Research (AACR) Annual Meeting 2026 by the German Cancer Research Center (DKFZ) will highlight Atera's ability to challenge prevailing assumptions and uncover cancer biology not accessible with legacy approaches, 10x Genomics said. Leading life sciences organisations and research institutions have already committed to using Atera at scale.